Rapport Therapeutics director Steven M Paul buys $974,000 of shares
Open market purchase reported on Form 4, filed Oct 22, 2026.
Snapshot
Steven M Paul, a director of Rapport Therapeutics (RAPP), bought 35,714 shares in open market purchases on Oct 22, 2026, about $974,000 at an average price of $27.28 a share, according to a Form 4 filed with the SEC on Oct 22, 2026.
- Independent Research
Market Data
| Company | 1D % | Price |
|---|---|---|
| ($RAPP) | ▼ −0.64% | 26.36 |
as of 12:31 ET · Realtime derived data
What We Know
The filing lists 1 open market purchase line: • Oct 22, 2026: 35,714 shares at $27.28.
After the last purchase, the filing reports 77,380 shares held indirectly in that account.
Octans View
The purchases raised the holding reported in that account by about 86%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.
Bear Case · Room for Disagreement
Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.
Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.
Chart
Sources
- [1]SEC EDGAR — Form 4 filed by Steven M Paul for Rapport Therapeutics, Oct 22, 2026
These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.
More on $RAPP
4 reports
Corebridge Financial 10% owner Nippon Life Insurance Co buys $6.8 million of shares
Open market purchase reported on Form 4, filed Oct 22, 2026.
Dole 10% owner Pale Fire Capital SE buys $8.6 million of shares
Open market purchase reported on Form 4, filed Oct 22, 2026.
New Germany Fund 10% owner Saba Capital Management L.P. buys $907,000 of shares
Open market purchase reported on Form 4, filed Oct 21, 2026.
Tenax Therapeutics 10% owner ADAR1 Capital Management LLC buys $1.5 million of shares
Open market purchase reported on Form 4, filed Oct 21, 2026.